Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Randomized Double-blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomenon

NCT01090492 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01090492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01090492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Randomized Double-blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomenon
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
August 4, 2010
Completion date
May 31, 2011
Enrollment
243 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral vascular disease, raynaud's disease